Edwards Lifesciences Corporation (NYSE:EW – Get Free Report) SVP Andrew Dahl sold 544 shares of Edwards Lifesciences stock in a transaction on Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the sale, the senior vice president directly owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Edwards Lifesciences Price Performance
Shares of EW stock opened at $90.86 on Tuesday. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The stock has a fifty day simple moving average of $89.64 and a two-hundred day simple moving average of $85.18. The stock has a market capitalization of $52.32 billion, a price-to-earnings ratio of 52.22, a P/E/G ratio of 2.37 and a beta of 0.85.
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.
Institutional Investors Weigh In On Edwards Lifesciences
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on EW shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Piper Sandler reissued an “overweight” rating and issued a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Citigroup upped their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Finally, Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $87.00 to $101.00 in a report on Friday, July 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.
Edwards Lifesciences Company Profile
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Stories
- Five stocks we like better than Edwards Lifesciences
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
